# Biotech Daily Digest â€” 2025-12-31

**4 items from 1 sources**

## Summary by Source

- Endpoints News: 4 items


## Endpoints News

- **[Biotechâ€™s groove is back for 2026 as XBI surges on M&A and lower rates](https://endpoints.news/biotechs-groove-is-back-for-2026-as-xbi-surges-on-ma-and-lower-rates/)**  
  _Tue, 30 Dec 2025 16:27:21 +0000_  
  Biotech executives and shareholders can breathe easier heading into the new year for the first time in nearly half a decade.

 The industryâ€™s leaders will arrive at Januaryâ€™s JP Morgan Healthcare Conference riding a surge ...

- **[Insilico caps the year with a soaring Hong Kong IPO](https://endpoints.news/insilico-caps-the-year-with-a-soaring-hong-kong-ipo/)**  
  _Tue, 30 Dec 2025 15:29:36 +0000_  
  Insilico Medicine, one of the original AI-driven drug discoverers, has stuck the landing after four years of trying to go public.

 The 11-year-old drug developer on Tuesday raised gross proceeds of ...

- **[Verastem axes Phase 1/2 lung cancer trial of Avmapki, pivots to KRAS blocker](https://endpoints.news/verastem-axes-phase-1-2-lung-cancer-trial-of-avmapki-pivots-to-kras-blocker/)**  
  _Tue, 30 Dec 2025 15:17:17 +0000_  
  Verastem Oncology is ending an early-stage trial of its MEK inhibitor Avmapki in lung cancer and pivoting to another program that it says could have a greater impact on patients.

 The biotech

- **[InflaRx seeks Gohibic revival in rare skin condition; ASK Pharm makes China rights deal](https://endpoints.news/ask-pharm-makes-china-rights-deal-unicycive-resubmits-kidney-drug-after-crl/)**  
  _Mon, 29 Dec 2025 17:42:33 +0000_  
  Plus, news about Unicycive, Harbour BioMed, Omeros, Gilead, Repare Therapeutics, Vaccinex and Foresee Pharmaceuticals.

 ðŸ’¼ InflaRx seeks to revive Gohibic in skin condition: After stopping a trial of the complement inhibitor in pyoderma gangrenosum ...
